Community-based trial of a triple-combination agent for the treatment of facial melasma

Cutis

Volumn 77, Issue 3, 2006, Pages 177-184

  Grimes, Pearl ^a,b,f,g,h   Kelly, A Paul ^c,g,h   Torok, Helen ^{d,g,i,j,k,l,m,n,o,p,q,r}   Willis, Isaac ^e  

^a Vitiligo and Pigmentation Institute of Southern California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KING DREW MEDICAL CENTER   (United States)

^d Trillium Creek Dermatology Center   (United States)

^e Northwest Medical Center   (United States)

^f Combe Inc ^*  (United States)

^g Galderma Laboratories LP   (United States)

^h Aveeno and Neutrogena ^*  (United States)

ⁱ Coria Laboratories Ltd ^*  (Spain)

^j Intendis Inc

^k Managed Care and Professional Affairs   (United States)

^l Dermik Laboratories   (United States)

^m Medicis   (France)

ⁿ Stiefel Laboratories Inc   (United States)

^o ALLERGAN INC   (United States)

^p AMGEN INC   (United States)

^q GENENTECH INC   (United States)

^r NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; FLUOCINOLONE ACETONIDE; HYDROQUINONE; HYDROQUINONE DERIVATIVE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOSIS; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PROSPECTIVE STUDY; SKIN DISEASE; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FACIAL DERMATOSES; FEMALE; FLUOCINOLONE ACETONIDE; HUMANS; HYDROQUINONES; MALE; MELANOSIS; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRETINOIN; UNITED STATES;

EID: 33645786362     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol. 1999;455:491-499.
2. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
3. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698-710.
4. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-577.
5. Giannotti B, Melli MC. Current approaches to the treatment of melasma. Clin Drug invest. 1995;10(suppl 2):57-64.
6. Griffiths CEM, Finkel LS, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. a vehicle-controlled, clinical trial. Br J Dermatol. 1993;129:415-421.
7. Verallo-Rowel VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol. 1989;143(suppl):58-61.
8. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;20:55-58.
9. Kimbrough-Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727-733.
10. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis. 1979;23:239-241.
11. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol. 1998;25:587-596.
12. Katsambas A, Antoniou CH. Melasma: classification and treatment. J Eur Acad Dermatol Venereal. 1995;4:217-223.
13. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
14. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark skinned patients. Dermatology. 2002;205:249-254.
15. Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828-832.
16. Guevara IL, Pandya AG. Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. Int J Dermatol. 2001;40:212-215.
17. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.
18. Balkrishnan R, Kelly AP, McMichael A, et al. Improved quality of life with effective therapy of facial melasma. J Drugs Dermatol. 2004;3:247-251.
19. Penney KB, Smith CJ, Allen JC. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J Invest Dermatol. 1984;82:308-310.
20. Craven NM, Griffiths CE. Topical retinoids and cutaneous biology. Clin Exp Dermatol. 1996;21:1-10.
21. Torok H, Taylor S, Baumann L, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005;4:592-597.
22. Kligman LH, Schwartz E, Lesnik RH, et al. Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect. Curr Probl Dermatol. 1993;21:79-88.
23. Lesnik RH, Mezick JA, Capetola RJ, et al. Topical all-trans retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. J Am Acad Dermatol 1989;21:186-190.
24. Schmied C, Saurat JH. Topical retinoic acid does not alter the vasoconstrictive properties of topical corticosteroids in humans. Dermatologica. 1991;182:107-111.
25. McMichael AJ, Griffiths CEM, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135:60-64.